Navigation Links
CryoLife Announces First Clinical Use of BioFoam(R)
Date:9/10/2009

ding statements regarding hopes that BioFoam will reduce the time required to achieve hemostasis during liver resection surgery and reduce the number of complications following surgery, potential distribution timing and uses and applications for BioFoam and timing of enrollment in the feasibility phase of the Company's BioFoam IDE submission. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that BioFoam may not prove safe or effective for its intended uses, that BioFoam may not achieve hemostasis in liver resections or reduce complications following surgery due to any number of factors that we will not be able to identify until further procedures are performed, that BioFoam may not be useful in other future surgical applications, that the Company may not start feasibility phase enrollment in quarter 4 of 2009 due to any number of factors, including unanticipated delays in obtaining FDA and U.S. Department of Defense approval, and that BioFoam development may not result in a commercial product on the time table anticipated, or at all, due to factors beyond our control, including potential lack of acceptance by the medical community. For additional risks impacting the Company's business, see the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's subsequent Form 10-Q filings. The Company does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com

    Media Contacts:

    D. Ashley Lee
    Executive Vice President, Chief Financial
    Officer and Chief Operating Officer
    Phone:  770-419-3355

    Dana H
'/>"/>
SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
2. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
3. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
4. CryoLife Reports Record First Quarter Revenues of $26.7 Million
5. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
6. CryoLife to Present at Sidotis 13th Annual New York Emerging Growth Institutional Forum
7. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
8. CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
9. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
10. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
11. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 Seahorse Bioscience, the industry ... the provider of XF Technology which is increasingly ... areas. As the links between mitochondrial function and ... is escalating rapidly.   Recently, 12 ... Publishing Group (NPG) featuring XF Technology, including Nature, ...
(Date:7/28/2015)... , July 21, 2015 Research and ... of the "Biomedical Refrigerators and Freezers Market ... and Forecast 2014 - 2022" report to ... refrigerators and freezers market has been segmented based ... blood banks, and others. The others segment includes ...
(Date:7/28/2015)... 28, 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) ... company, today announced that its stockholders approved an increase ... of the Company from 1,000,000,000 to 2,500,000,000 at its ... at the Law Offices of Nixon Peabody LLP in ... there were 480,655,929 shares of common stock represented either ...
(Date:7/28/2015)... July 28, 2015 BioStructures, LLC, a ... hit a milestone of 4,000 implantations of Signafuse® ... cleared in early 2014 as a bone void ... fusion procedures.  This is a distinguished status among ... 6% of new synthetic products have received clearance ...
Breaking Biology Technology:XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Revolutionary Bone Graft Exceeds Expectations 2
... Chromos Molecular,Systems Inc. ("Chromos" or the "Company") announced ... in the Provinces,of British Columbia, Alberta, Manitoba, Ontario ... the Company effective July 22, 2008. As a,result, ... against the,Company., The Company continues to review ...
... a video interview, new CEO,Andrew Witty comments on GSK,s second ... for the business., The new strategic ... business - Deliver more products of value - ... are available now on, http://www.cantos.com . It,s free to view. ...
... JOLLA, Calif., July 23 Duska Therapeutics,Inc. (OTC ... has,submitted for comment a synopsis of a proposed ... to the U.S. Food and Drug Administration,s (the,"FDA") ... on recent communications with the FDA, including a ...
Cached Biology Technology:Chromos Announces Full Revocation of Cease Trade Orders 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 3Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 4
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/2/2015)... , June 25, 2015 ... the addition of the "Natural Language Processing ... (Recognition, IVR, OCR, Pattern & Image Recognition) - ... offering. The key vendors occupying the ... IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute ...
(Date:6/29/2015)... , June 24, 2015 ... of the "Latin America Biomedical Sensors Market - ... offering. The Latin America Biomedical Sensors market ... CAGR of 2.04% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... farming and relieve the pressure on overexploited fish stocks. ... fish escape? Researchers at the University of Gothenburg have ... are urging caution:,-Until further notice transgenic fish should be ... at the Department of Zoology, University of Gothenburg. ...
... A research report featured on the cover of the September ... http://www.fasebj.org ) describes how Australian scientists developed a new gene ... to transport their cargo into our cells. As a result ... cell,s nucleus far more efficiently than in the past, raising ...
... from natural coal deposits in the Gulf of Alaska ... the Exxon Valdez tanker catastrophe. This clearly disproves the ... observed environmental damage. PAH pollutants were blamed for the ... Alaska. Then a dispute erupted over the origins of ...
Cached Biology News:Risks involved with transgenic fish 2Finding the ZIP-code for gene therapy: Scientists imitate viruses to deliver therapeutic genes 2Bioavailable contaminants come from the Exxon Valdez oil catastrophe 2
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Anti-hamster Ig HRP detection kit...
...
...
Biology Products: